Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
О безопасности применения глюкозамина сульфата у пациентов с резистентностью к инсулину
О безопасности применения глюкозамина сульфата у пациентов с резистентностью к инсулину
Громова О.А., Торшин И.Ю., Лила А.М. и др. О безопасности применения глюкозамина сульфата у пациентов с резистентностью к инсулину. Consilium Medicum. 2019; 21 (4): 75–83. DOI: 10.26442/20751753.2019.4.190309
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Цель. Инсулинорезистентность, метаболический синдром и сахарный диабет 2-го типа (СД 2) стимулируют развитие хронического воспаления и затрудняют реабилитацию пациентов с любой коморбидной патологией. В частности, СД 2 нарушает метаболизм хряща, приводя к остеоартриту (ОА). Для лечения артропатогенных последствий СД 2 используются нестероидные противовоспалительные препараты (НПВП), препараты на основе глюкозамина сульфата (ГС) и хондроитина сульфата (ХС).
Материалы и методы. Компьютерный анализ текстов 21 777 публикаций.
Результаты. ГС является одним из наиболее безопасных видов терапии ОА. Экспериментальные и клинические исследования показали, что ГС может безопасно использоваться для лечения ОА у пациентов с СД 2. Противовоспалительные эффекты ГС и ингибирование молекулами ГС процессов О-ацетилглюкозаминирования указывают на возможность профилактики осложнений СД 2.
Заключение. Несмотря на присутствие корня «глюко-» в названии ГС, данное вещество не стимулирует формирование или прогрессирование инсулинорезистентности.
Ключевые слова: остеоартрит, инсулинорезистентность, глюкозамина сульфат, хондроитина сульфат, фармакобезопасность, Сустагард Артро, Хондрогард.
Материалы и методы. Компьютерный анализ текстов 21 777 публикаций.
Результаты. ГС является одним из наиболее безопасных видов терапии ОА. Экспериментальные и клинические исследования показали, что ГС может безопасно использоваться для лечения ОА у пациентов с СД 2. Противовоспалительные эффекты ГС и ингибирование молекулами ГС процессов О-ацетилглюкозаминирования указывают на возможность профилактики осложнений СД 2.
Заключение. Несмотря на присутствие корня «глюко-» в названии ГС, данное вещество не стимулирует формирование или прогрессирование инсулинорезистентности.
Ключевые слова: остеоартрит, инсулинорезистентность, глюкозамина сульфат, хондроитина сульфат, фармакобезопасность, Сустагард Артро, Хондрогард.
________________________________________________
Aim. Insulin resistance, metabolic syndrome and type 2 diabetes mellitus (T2DM) stimulate the development of chronic inflammation and make it difficult to rehabilitate patients with any comorbid pathology. In particular, T2DM impairs cartilage metabolism, leading to osteoarthritis (OA). For the treatment of arthropathogenic effects of diabetes mellitus, non-steroidal anti-inflammatory drugs (NSAIDs), drugs based on glucosamine sulfate (GS) and chondroitin sulfate (CS) are used.
Materials and methods. Computer analysis of texts 21 777 publications.
Results. GS is one of the safest OA therapies. Nexperimental and clinical studies have shown that HS can safely be used to treat OA in patients with type 2 diabetes. The anti-inflammatory effects of GS and the CS inhibition of O-acetylglucosamination processes by the molecules indicate the possibility of preventing the complications of type 2 diabetes.
Conclusion. Despite the presence of the root "gluco" in the name of the GS, this substance does not stimulate the formation or progression of insulin resistance.
Key words: osteoarthritis, insulin resistance, glucosamine sulfate, chondroitin sulfate, pharma-safety, Sustaguard Arthro, Chondroguard.
Materials and methods. Computer analysis of texts 21 777 publications.
Results. GS is one of the safest OA therapies. Nexperimental and clinical studies have shown that HS can safely be used to treat OA in patients with type 2 diabetes. The anti-inflammatory effects of GS and the CS inhibition of O-acetylglucosamination processes by the molecules indicate the possibility of preventing the complications of type 2 diabetes.
Conclusion. Despite the presence of the root "gluco" in the name of the GS, this substance does not stimulate the formation or progression of insulin resistance.
Key words: osteoarthritis, insulin resistance, glucosamine sulfate, chondroitin sulfate, pharma-safety, Sustaguard Arthro, Chondroguard.
Полный текст
Список литературы
1. Tilling LM, Darawil K, Britton M. Falls as a complication of diabetes mellitus in older people. J Diabetes Complications 2006; 20 (3): 158–62. PMID: 16632235.
2. Bianchi L, Volpato S. Muscle dysfunction in type 2 diabetes: a major threat to patient's mobility and independence. Acta Diabetol 2016; 53 (6): 879–89. DOI: 10.1007/s00592-016-0880-y. PMID: 27393005.
3. Reginato AM, Riera H, Vera M et al. Osteoarthritis in Latin America: Study of Demographic and Clinical Characteristics in 3040 Patients. J Clin Rheumatol 2015; 21 (8): 391–7. DOI: 10.1097/RHU.0000000000000281. PMID: 26457483.
4. Громова О.А., Торшин И.Ю., Лила А.М., Громов А.Н. Молекулярные механизмы глюкозамина сульфата при лечении дегенеративно-дистрофических заболеваний суставов и позвоночника: результаты протеомного анализа. Неврология, нейропсихиатрия, психосоматика. 2018; 10 (2): 38–44. DOI: 10.14412/2074-2711-2018-2-38-44
[Gromova O.A., Torshin I.Iu., Lila A.M., Gromov A.N. Molekuliarnye mekhanizmy gliukozamina sul'fata pri lechenii degenerativno-distroficheskikh zabolevanii sustavov i pozvonochnika: rezul'taty proteomnogo analiza. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2018; 10 (2): 38–44. DOI: 10.14412/2074-2711-2018-2-38-44 (in Russian).]
5. Лила А.М., Громова О.А., Торшин И.Ю. и др. Молекулярные эффекты хондрогарда при остеоартрите и грыжах межпозвоночного диска. Неврология, нейропсихиатрия, психосоматика. 2017; 9 (3): 88–97.
[Lila A.M., Gromova O.A., Torshin I.Iu. et al. Molekuliarnye effekty khondrogarda pri osteoartrite i gryzhakh mezhpozvonochnogo diska. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2017; 9 (3): 88–97 (in Russian).]
6. Melgar-Lesmes P, Garcia-Polite F, Del-Rey-Puech P et al. Treatment with chondroitin sulfate to modulate inflammation and atherogenesis in obesity. Atherosclerosis 2015; 245: 82–7.
7. Bell GA, Kantor ED, Lampe JW et al. Use of Glucosamine and Chondroitin in Relation to Mortality. Eur J Epidemiol 2012; 27 (8): 593–603.
8. Lenox CE, Lunn KF. Effects of glucosamine-chondroitin sulfate supplementation on serum fructosamine concentration in healthy dogs. J Am Vet Med Assoc 2010; 236 (2): 183–6. DOI: 10.2460/javma.236.2.183. PMID: 20074008.
9. Stumpf JL, Lin SW. Effect of glucosamine on glucose control. Ann Pharmacother 2006; 40 (4): 694–8. DOI: 10.1345/aph.1E658. PMID: 16569816.
10. Torshin IYu, Rudakov KV. On the theoretical basis of metric analysis of poorly formalized problems of recognition and classification. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications) 2015; 25 (4): 577–87.
11. Torshin IY, Rudakov KV. On metric spaces arising during formalization of problems of recognition and classification. Part 1: properties of compactness. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications) 2016; 26 (2): 274–84.
12. Torshin IYu, Rudakov KV. On metric spaces arising during formalization of problems of recognition and classification. Рart 2: density properties. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications) 2016, 26 (3): 483–96.
13. Torshin IY, Rudakov KV. Combinatorial analysis of the solvability properties of the problems of recognition and completeness of algorithmic models. Рart 1: factorization approach. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications) 2017; 27 (1): 16–28.
14. Torshin IYu, Rudakov KV. Combinatorial analysis of the solvability properties of the problems of recognition and completeness of algorithmic models. Part 2: metric approach within the framework of the theory of classification of feature values. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications) 2017; 27 (2): 184–99.
15. Garcilazo C, Cavallasca JA, Musuruana JL. Shoulder manifestations of diabetes mellitus. Curr Diabetes Rev 2010; 6 (5): 334–40. PMID: 20701586.
16. Veronese N, Cooper C, Reginster JY et al. Type 2 diabetes mellitus and osteoarthritis. Semin Arthritis Rheum 2019; 18: 30586–9. DOI: 10.1016/j.semarthrit.2019.01.005. PMID: 30712918.
17. Громова О.А., Торшин И.Ю., Лила А.М. и др. Молекулярные механизмы миопротективного действия хондроитина сульфата и глюкозамина сульфата при саркопении. Неврология, нейропсихиатрия, психосоматика. 2019; 11 (1): 117–24. DOI: 10.14412/2074-2711-2019-1-117-124.
[Gromova O.A., Torshin I.Iu., Lila A.M. et al. Molekuliarnye mekhanizmy mioprotektivnogo deistviia khondroitina sul'fata i gliukozamina sul'fata pri sarkopenii. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2019; 11 (1): 117–24. DOI: 10.14412/2074-2711-2019-1-117-124 (in Russian).]
18. Громова О.А., Торшин И.Ю., Лила А.М. и др. Дифференциальный хемореактомный анализ глюкозамина сульфата и нестероидных противовоспалительных препаратов: перспективные синергичные комбинации. Соврем. ревматология. 2018; 12 (2): 36–43.
[Gromova O.A., Torshin I.Iu., Lila A.M. et al. Differentsial'nyi khemoreaktomnyi analiz gliukozamina sul'fata i nesteroidnykh protivovospalitel'nykh preparatov: perspektivnye sinergichnye kombinatsii. Sovrem. revmatologiia. 2018; 12 (2): 36–43 (in Russian).]
19. Торшин И.Ю., Громова О.А., Лила А.М. и др. Результаты постгеномного анализа молекулы глюкозамина сульфата указывают на перспективы лечения коморбидных заболеваний. Соврем. ревматология. 2018; 12 (4): 129–36.
[Torshin I.Iu., Gromova O.A., Lila A.M. et al. Rezul'taty postgenomnogo analiza molekuly gliukozamina sul'fata ukazyvaiut na perspektivy lecheniia komorbidnykh zabolevanii. Sovrem. revmatologiia. 2018; 12 (4): 129–36 (in Russian).]
20. Shi H, Munk A, Nielsen TS et al. Skeletal muscle O-GlcNAc transferase is important for muscle energy homeostasis and whole-body insulin sensitivity. Mol Metab 2018; 11: 160–77. DOI: 10.1016/j.molmet.2018.02.010. PMID: 29525407.
21. Lazarus MB, Jiang J, Gloster TM et al. Structural snapshots of the reaction coordinate for O-GlcNAc transferase. Nat Chem Biol 2012; 8 (12): 966–8. DOI: 10.1038/nchembio.1109. PMID: 23103939; PMCID: PMC3508357.
22. Lorenzo C, Festa A, Hanley AJ et al. Novel Protein Glycan-Derived Markers of Systemic Inflammation and C-Reactive Protein in Relation to Glycemia, Insulin Resistance, and Insulin Secretion. Diabetes Care 2017; 40 (3): 375–82. DOI: 10.2337/dc16-1569. PMID: 28031420.
23. Banerjee PS, Lagerlof O, Hart GW. Roles of O-GlcNAc in chronic diseases of aging. Mol Aspects Med 2016; 51: 1–15. DOI: 10.1016/j.mam.2016.05.005. PMID: 27259471.
24. Hwang SY, Shin JH, Hwang JS. Glucosamine exerts a neuroprotective effect via suppression of inflammationin rat brain ischemia/reperfusion injury. Glia 2010; 58 (15): 1881–92. DOI: 10.1002/glia.21058. PMID: 20737476.
25. Whelan SA, Dias WB, Thiruneelakantapillai L et al. Regulation of insulin receptor substrate 1 (IRS-1)/AKT kinase-mediated insulin signaling by O-Linked beta-N-acetylglucosamine in 3T3-L1 adipocytes. J Biol Chem 2010; 285 (8): 5204–11. DOI: 10.1074/jbc.M109.077818. PMID: 20018868
26. Baldini SF, Steenackers A, Olivier-Van Stichelen S. Glucokinase expression is regulated by glucose through O-GlcNAc glycosylation. Biochem Biophys Res Commun 2016; 478 (2): 942–8. DOI: 10.1016/j.bbrc.2016.08.056. PMID: 27520373.
27. Park S, Pak J, Jang I, Cho JW. Inhibition of mTOR affects protein stability of OGT. Biochem Biophys Res Commun 2014; 453 (2): 208–12. DOI: 10.1016/j.bbrc.2014.05.047. PMID: 24858682.
28. Al-Kurdi ZI, Chowdhry BZ, Leharne SA et al. Influence of glucosamine on the bioactivity of insulin delivered subcutaneously and in an oral nanodelivery system. Drug Des Devel Ther 2015; 9: 6167–76. DOI: 10.2147/DDDT.S91974. PMID: 26640369.
29. Chien MW, Lin MH, Huang SH et al. Glucosamine Modulates T Cell Differentiation through Down-regulating N-Linked Glycosylation of CD25. J Biol Chem 2015; 290 (49): 29329–44. DOI: 10.1074/jbc.M115.674671. PMID: 26468284.
30. Barrientos C, Racotta R, Quevedo L. Glucosamine attenuates increases of intraabdominal fat, serum leptin levels, and insulin resistance induced by a high-fat diet in rats. Nutr Res 2010; 30 (11): 791–800. DOI: 10.1016/j.nutres.2010.10.008. PMID: 21130299
31. Balkan B, Dunning BE. Glucosamine inhibits glucokinase in vitro and produces a glucose-specific impairment of in vivo insulin secretion in rats. Diabetes 1994; 43 (10): 1173–9. PMID: 7926284.
32. Simon RR, Marks V, Leeds AR, Anderson JW. A comprehensive review of oral glucosamine use and effects on glucose metabolism in normal and diabetic individuals. Diabetes Metab Res Rev 2011; 27 (1): 14–27. DOI: 10.1002/dmrr.1150. PMID: 21218504.
33. Tannis AJ, Barban J, Conquer JA. Effect of glucosamine supplementation on fasting and non-fasting plasma glucose and serum insulin concentrations in healthy individuals. Osteoarthritis Cartilage 2004; 12 (6): 506–11. DOI: 10.1016/j.joca.2004.03.001. PMID: 15135147.
34. Saghafi M, Karimi M, Bonakdaran S, Massoudnia N. Oral Glucosamine Effect on Blood Glucose and Insulin Levels in Patients With Non-Diabetic Osteoarthritis: A Double-Blind, Placebo-Controlled Clinical Trial. Arch Rheumatol 2016; 31 (4): 340–5. DOI: 10.5606/ArchRheumatol.2016.5632. PMID: 30375553.
35. Gommans YMM, Runhaar J, Jacobs ML, Bierma-Zeinstra SMA. The Effect of Prolonged Glucosamine Usage on HbA1c Levels and New-Onset Diabetes Mellitus in Overweight and Obese Middle-Aged Women. Am J Med 2017; 130 (6): 731–7.e6. DOI: 10.1016/j.amjmed.2016.11.038. PMID: 28011309.
36. Albert SG, Oiknine RF, Parseghian S et al. The effect of glucosamine on Serum HDL cholesterol and apolipoprotein AI levels in people with diabetes. Diabetes Care 2007; 30 (11): 2800–3. DOI: 10.2337/dc07-0545. PMID: 17682119.
37. Scroggie DA, Albright A, Harris MD. The effect of glucosamine-chondroitin supplementation on glycosylated hemoglobin levels in patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized clinical trial. Arch Intern Med 2003; 163 (13): 1587–90. DOI: 10.1001/archinte.163.13.1587. PMID: 12860582.
38. Nevado-Holgado AJ, Kim CH, Winchester L et al. Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK Biobank. BMJ Open 2016; 6 (11): e012177. DOI: 10.1136/bmjopen-2016-012177. PMID: 27903560.
39. Наумов А.В., Ткачева О.Н., Ховасова Н.О. Обострения хронической боли в спине у коморбидных больных: терапия на перспективу. РМЖ. Медицинское обозрение. 2018; 5: 35–42.
[Naumov A.V., Tkacheva O.N., Khovasova N.O. Obostreniia khronicheskoi boli v spine u komorbidnykh bol'nykh: terapiia na perspektivu. RMZh. Meditsinskoe obozrenie. 2018; 5: 35–42 (in Russian).]
40. Удовика М.И. Сравнительная эффективность инъекционных и пероральных симптоматических препаратов медленного действия в терапии первичного и посттравматического остеоартроза коленных суставов. РМЖ. 2017; 4: 446–50.
[Udovika M.I. Sravnitel'naia effektivnost' in"ektsionnykh i peroral'nykh simptomaticheskikh preparatov medlennogo deistviia v terapii pervichnogo i posttravmaticheskogo osteoartroza kolennykh sustavov. RMZh. 2017; 4: 446–50 (in Russian).]
41. Рандомизированное слепое многоцентровое плацебо-контролируемое клиническое исследование по изучению эффективности и безопасности препарата Сустагард® Артро, раствор для внутримышечного введения (ЗАО «ФармФирма “Сотекс”», Россия) у пациентов с остеоартрозом коленного сустава (гонартрозом) в параллельных группах, РКИ №60 от 12.02.2014, Фаза исследования III. Обращение к сайту 25 марта 2019. http://grls.rosminzdrav.ru
[Randomizirovannoe slepoe mnogotsentrovoe platsebo-kontroliruemoe klinicheskoe issledovanie po izucheniiu effektivnosti i bezopasnosti preparata SustagardR Artro, rastvor dlia vnutrimyshechnogo vvedeniia (ZAO "FarmFirma “Soteks”", Rossiia) u patsientov s osteoartrozom kolennogo sustava (gonartrozom) v parallel'nykh gruppakh, RKI №60 ot 12.02.2014, Faza issledovaniia III. Obrashchenie k saitu 25 marta 2019. http://grls.rosminzdrav.ru (in Russian).]
42. Четина Е.В., Шарапова Е.П., Кашеварова Н.Г. и др. Экспрессия генов метаболизма глюкозы и деструкции суставов при развитии сахарного диабета у больных остеоартритом. Соврем. ревматология. 2019; 13 (1): 64–70.
[Chetina E.V., Sharapova E.P., Kashevarova N.G. et al. Ekspressiia genov metabolizma gliukozy i destruktsii sustavov pri razvitii sakharnogo diabeta u bol'nykh osteoartritom. Sovrem. revmatologiia. 2019; 13 (1): 64–70 (in Russian).]
2. Bianchi L, Volpato S. Muscle dysfunction in type 2 diabetes: a major threat to patient's mobility and independence. Acta Diabetol 2016; 53 (6): 879–89. DOI: 10.1007/s00592-016-0880-y. PMID: 27393005.
3. Reginato AM, Riera H, Vera M et al. Osteoarthritis in Latin America: Study of Demographic and Clinical Characteristics in 3040 Patients. J Clin Rheumatol 2015; 21 (8): 391–7. DOI: 10.1097/RHU.0000000000000281. PMID: 26457483.
4. Gromova O.A., Torshin I.Iu., Lila A.M., Gromov A.N. Molekuliarnye mekhanizmy gliukozamina sul'fata pri lechenii degenerativno-distroficheskikh zabolevanii sustavov i pozvonochnika: rezul'taty proteomnogo analiza. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2018; 10 (2): 38–44. DOI: 10.14412/2074-2711-2018-2-38-44 (in Russian).
5. Lila A.M., Gromova O.A., Torshin I.Iu. et al. Molekuliarnye effekty khondrogarda pri osteoartrite i gryzhakh mezhpozvonochnogo diska. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2017; 9 (3): 88–97 (in Russian).
6. Melgar-Lesmes P, Garcia-Polite F, Del-Rey-Puech P et al. Treatment with chondroitin sulfate to modulate inflammation and atherogenesis in obesity. Atherosclerosis 2015; 245: 82–7.
7. Bell GA, Kantor ED, Lampe JW et al. Use of Glucosamine and Chondroitin in Relation to Mortality. Eur J Epidemiol 2012; 27 (8): 593–603.
8. Lenox CE, Lunn KF. Effects of glucosamine-chondroitin sulfate supplementation on serum fructosamine concentration in healthy dogs. J Am Vet Med Assoc 2010; 236 (2): 183–6. DOI: 10.2460/javma.236.2.183. PMID: 20074008.
9. Stumpf JL, Lin SW. Effect of glucosamine on glucose control. Ann Pharmacother 2006; 40 (4): 694–8. DOI: 10.1345/aph.1E658. PMID: 16569816.
10. Torshin IYu, Rudakov KV. On the theoretical basis of metric analysis of poorly formalized problems of recognition and classification. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications) 2015; 25 (4): 577–87.
11. Torshin IY, Rudakov KV. On metric spaces arising during formalization of problems of recognition and classification. Part 1: properties of compactness. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications) 2016; 26 (2): 274–84.
12. Torshin IYu, Rudakov KV. On metric spaces arising during formalization of problems of recognition and classification. Рart 2: density properties. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications) 2016, 26 (3): 483–96.
13. Torshin IY, Rudakov KV. Combinatorial analysis of the solvability properties of the problems of recognition and completeness of algorithmic models. Рart 1: factorization approach. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications) 2017; 27 (1): 16–28.
14. Torshin IYu, Rudakov KV. Combinatorial analysis of the solvability properties of the problems of recognition and completeness of algorithmic models. Part 2: metric approach within the framework of the theory of classification of feature values. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications) 2017; 27 (2): 184–99.
15. Garcilazo C, Cavallasca JA, Musuruana JL. Shoulder manifestations of diabetes mellitus. Curr Diabetes Rev 2010; 6 (5): 334–40. PMID: 20701586.
16. Veronese N, Cooper C, Reginster JY et al. Type 2 diabetes mellitus and osteoarthritis. Semin Arthritis Rheum 2019; 18: 30586–9. DOI: 10.1016/j.semarthrit.2019.01.005. PMID: 30712918.
17. Gromova O.A., Torshin I.Iu., Lila A.M. et al. Molekuliarnye mekhanizmy mioprotektivnogo deistviia khondroitina sul'fata i gliukozamina sul'fata pri sarkopenii. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2019; 11 (1): 117–24. DOI: 10.14412/2074-2711-2019-1-117-124 (in Russian).
18. Gromova O.A., Torshin I.Iu., Lila A.M. et al. Differentsial'nyi khemoreaktomnyi analiz gliukozamina sul'fata i nesteroidnykh protivovospalitel'nykh preparatov: perspektivnye sinergichnye kombinatsii. Sovrem. revmatologiia. 2018; 12 (2): 36–43 (in Russian).
19. Torshin I.Iu., Gromova O.A., Lila A.M. et al. Rezul'taty postgenomnogo analiza molekuly gliukozamina sul'fata ukazyvaiut na perspektivy lecheniia komorbidnykh zabolevanii. Sovrem. revmatologiia. 2018; 12 (4): 129–36 (in Russian).
20. Shi H, Munk A, Nielsen TS et al. Skeletal muscle O-GlcNAc transferase is important for muscle energy homeostasis and whole-body insulin sensitivity. Mol Metab 2018; 11: 160–77. DOI: 10.1016/j.molmet.2018.02.010. PMID: 29525407.
21. Lazarus MB, Jiang J, Gloster TM et al. Structural snapshots of the reaction coordinate for O-GlcNAc transferase. Nat Chem Biol 2012; 8 (12): 966–8. DOI: 10.1038/nchembio.1109. PMID: 23103939; PMCID: PMC3508357.
22. Lorenzo C, Festa A, Hanley AJ et al. Novel Protein Glycan-Derived Markers of Systemic Inflammation and C-Reactive Protein in Relation to Glycemia, Insulin Resistance, and Insulin Secretion. Diabetes Care 2017; 40 (3): 375–82. DOI: 10.2337/dc16-1569. PMID: 28031420.
23. Banerjee PS, Lagerlof O, Hart GW. Roles of O-GlcNAc in chronic diseases of aging. Mol Aspects Med 2016; 51: 1–15. DOI: 10.1016/j.mam.2016.05.005. PMID: 27259471.
24. Hwang SY, Shin JH, Hwang JS. Glucosamine exerts a neuroprotective effect via suppression of inflammationin rat brain ischemia/reperfusion injury. Glia 2010; 58 (15): 1881–92. DOI: 10.1002/glia.21058. PMID: 20737476.
25. Whelan SA, Dias WB, Thiruneelakantapillai L et al. Regulation of insulin receptor substrate 1 (IRS-1)/AKT kinase-mediated insulin signaling by O-Linked beta-N-acetylglucosamine in 3T3-L1 adipocytes. J Biol Chem 2010; 285 (8): 5204–11. DOI: 10.1074/jbc.M109.077818. PMID: 20018868
26. Baldini SF, Steenackers A, Olivier-Van Stichelen S. Glucokinase expression is regulated by glucose through O-GlcNAc glycosylation. Biochem Biophys Res Commun 2016; 478 (2): 942–8. DOI: 10.1016/j.bbrc.2016.08.056. PMID: 27520373.
27. Park S, Pak J, Jang I, Cho JW. Inhibition of mTOR affects protein stability of OGT. Biochem Biophys Res Commun 2014; 453 (2): 208–12. DOI: 10.1016/j.bbrc.2014.05.047. PMID: 24858682.
28. Al-Kurdi ZI, Chowdhry BZ, Leharne SA et al. Influence of glucosamine on the bioactivity of insulin delivered subcutaneously and in an oral nanodelivery system. Drug Des Devel Ther 2015; 9: 6167–76. DOI: 10.2147/DDDT.S91974. PMID: 26640369.
29. Chien MW, Lin MH, Huang SH et al. Glucosamine Modulates T Cell Differentiation through Down-regulating N-Linked Glycosylation of CD25. J Biol Chem 2015; 290 (49): 29329–44. DOI: 10.1074/jbc.M115.674671. PMID: 26468284.
30. Barrientos C, Racotta R, Quevedo L. Glucosamine attenuates increases of intraabdominal fat, serum leptin levels, and insulin resistance induced by a high-fat diet in rats. Nutr Res 2010; 30 (11): 791–800. DOI: 10.1016/j.nutres.2010.10.008. PMID: 21130299
31. Balkan B, Dunning BE. Glucosamine inhibits glucokinase in vitro and produces a glucose-specific impairment of in vivo insulin secretion in rats. Diabetes 1994; 43 (10): 1173–9. PMID: 7926284.
32. Simon RR, Marks V, Leeds AR, Anderson JW. A comprehensive review of oral glucosamine use and effects on glucose metabolism in normal and diabetic individuals. Diabetes Metab Res Rev 2011; 27 (1): 14–27. DOI: 10.1002/dmrr.1150. PMID: 21218504.
33. Tannis AJ, Barban J, Conquer JA. Effect of glucosamine supplementation on fasting and non-fasting plasma glucose and serum insulin concentrations in healthy individuals. Osteoarthritis Cartilage 2004; 12 (6): 506–11. DOI: 10.1016/j.joca.2004.03.001. PMID: 15135147.
34. Saghafi M, Karimi M, Bonakdaran S, Massoudnia N. Oral Glucosamine Effect on Blood Glucose and Insulin Levels in Patients With Non-Diabetic Osteoarthritis: A Double-Blind, Placebo-Controlled Clinical Trial. Arch Rheumatol 2016; 31 (4): 340–5. DOI: 10.5606/ArchRheumatol.2016.5632. PMID: 30375553.
35. Gommans YMM, Runhaar J, Jacobs ML, Bierma-Zeinstra SMA. The Effect of Prolonged Glucosamine Usage on HbA1c Levels and New-Onset Diabetes Mellitus in Overweight and Obese Middle-Aged Women. Am J Med 2017; 130 (6): 731–7.e6. DOI: 10.1016/j.amjmed.2016.11.038. PMID: 28011309.
36. Albert SG, Oiknine RF, Parseghian S et al. The effect of glucosamine on Serum HDL cholesterol and apolipoprotein AI levels in people with diabetes. Diabetes Care 2007; 30 (11): 2800–3. DOI: 10.2337/dc07-0545. PMID: 17682119.
37. Scroggie DA, Albright A, Harris MD. The effect of glucosamine-chondroitin supplementation on glycosylated hemoglobin levels in patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized clinical trial. Arch Intern Med 2003; 163 (13): 1587–90. DOI: 10.1001/archinte.163.13.1587. PMID: 12860582.
38. Nevado-Holgado AJ, Kim CH, Winchester L et al. Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK Biobank. BMJ Open 2016; 6 (11): e012177. DOI: 10.1136/bmjopen-2016-012177. PMID: 27903560.
39. Naumov A.V., Tkacheva O.N., Khovasova N.O. Obostreniia khronicheskoi boli v spine u komorbidnykh bol'nykh: terapiia na perspektivu. RMZh. Meditsinskoe obozrenie. 2018; 5: 35–42 (in Russian).
40. Udovika M.I. Sravnitel'naia effektivnost' in"ektsionnykh i peroral'nykh simptomaticheskikh preparatov medlennogo deistviia v terapii pervichnogo i posttravmaticheskogo osteoartroza kolennykh sustavov. RMZh. 2017; 4: 446–50 (in Russian).
41. Randomizirovannoe slepoe mnogotsentrovoe platsebo-kontroliruemoe klinicheskoe issledovanie po izucheniiu effektivnosti i bezopasnosti preparata SustagardR Artro, rastvor dlia vnutrimyshechnogo vvedeniia (ZAO "FarmFirma “Soteks”", Rossiia) u patsientov s osteoartrozom kolennogo sustava (gonartrozom) v parallel'nykh gruppakh, RKI №60 ot 12.02.2014, Faza issledovaniia III. Obrashchenie k saitu 25 marta 2019. http://grls.rosminzdrav.ru (in Russian).
42. Chetina E.V., Sharapova E.P., Kashevarova N.G. et al. Ekspressiia genov metabolizma gliukozy i destruktsii sustavov pri razvitii sakharnogo diabeta u bol'nykh osteoartritom. Sovrem. revmatologiia. 2019; 13 (1): 64–70 (in Russian).
2. Bianchi L, Volpato S. Muscle dysfunction in type 2 diabetes: a major threat to patient's mobility and independence. Acta Diabetol 2016; 53 (6): 879–89. DOI: 10.1007/s00592-016-0880-y. PMID: 27393005.
3. Reginato AM, Riera H, Vera M et al. Osteoarthritis in Latin America: Study of Demographic and Clinical Characteristics in 3040 Patients. J Clin Rheumatol 2015; 21 (8): 391–7. DOI: 10.1097/RHU.0000000000000281. PMID: 26457483.
4. Громова О.А., Торшин И.Ю., Лила А.М., Громов А.Н. Молекулярные механизмы глюкозамина сульфата при лечении дегенеративно-дистрофических заболеваний суставов и позвоночника: результаты протеомного анализа. Неврология, нейропсихиатрия, психосоматика. 2018; 10 (2): 38–44. DOI: 10.14412/2074-2711-2018-2-38-44
[Gromova O.A., Torshin I.Iu., Lila A.M., Gromov A.N. Molekuliarnye mekhanizmy gliukozamina sul'fata pri lechenii degenerativno-distroficheskikh zabolevanii sustavov i pozvonochnika: rezul'taty proteomnogo analiza. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2018; 10 (2): 38–44. DOI: 10.14412/2074-2711-2018-2-38-44 (in Russian).]
5. Лила А.М., Громова О.А., Торшин И.Ю. и др. Молекулярные эффекты хондрогарда при остеоартрите и грыжах межпозвоночного диска. Неврология, нейропсихиатрия, психосоматика. 2017; 9 (3): 88–97.
[Lila A.M., Gromova O.A., Torshin I.Iu. et al. Molekuliarnye effekty khondrogarda pri osteoartrite i gryzhakh mezhpozvonochnogo diska. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2017; 9 (3): 88–97 (in Russian).]
6. Melgar-Lesmes P, Garcia-Polite F, Del-Rey-Puech P et al. Treatment with chondroitin sulfate to modulate inflammation and atherogenesis in obesity. Atherosclerosis 2015; 245: 82–7.
7. Bell GA, Kantor ED, Lampe JW et al. Use of Glucosamine and Chondroitin in Relation to Mortality. Eur J Epidemiol 2012; 27 (8): 593–603.
8. Lenox CE, Lunn KF. Effects of glucosamine-chondroitin sulfate supplementation on serum fructosamine concentration in healthy dogs. J Am Vet Med Assoc 2010; 236 (2): 183–6. DOI: 10.2460/javma.236.2.183. PMID: 20074008.
9. Stumpf JL, Lin SW. Effect of glucosamine on glucose control. Ann Pharmacother 2006; 40 (4): 694–8. DOI: 10.1345/aph.1E658. PMID: 16569816.
10. Torshin IYu, Rudakov KV. On the theoretical basis of metric analysis of poorly formalized problems of recognition and classification. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications) 2015; 25 (4): 577–87.
11. Torshin IY, Rudakov KV. On metric spaces arising during formalization of problems of recognition and classification. Part 1: properties of compactness. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications) 2016; 26 (2): 274–84.
12. Torshin IYu, Rudakov KV. On metric spaces arising during formalization of problems of recognition and classification. Рart 2: density properties. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications) 2016, 26 (3): 483–96.
13. Torshin IY, Rudakov KV. Combinatorial analysis of the solvability properties of the problems of recognition and completeness of algorithmic models. Рart 1: factorization approach. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications) 2017; 27 (1): 16–28.
14. Torshin IYu, Rudakov KV. Combinatorial analysis of the solvability properties of the problems of recognition and completeness of algorithmic models. Part 2: metric approach within the framework of the theory of classification of feature values. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications) 2017; 27 (2): 184–99.
15. Garcilazo C, Cavallasca JA, Musuruana JL. Shoulder manifestations of diabetes mellitus. Curr Diabetes Rev 2010; 6 (5): 334–40. PMID: 20701586.
16. Veronese N, Cooper C, Reginster JY et al. Type 2 diabetes mellitus and osteoarthritis. Semin Arthritis Rheum 2019; 18: 30586–9. DOI: 10.1016/j.semarthrit.2019.01.005. PMID: 30712918.
17. Громова О.А., Торшин И.Ю., Лила А.М. и др. Молекулярные механизмы миопротективного действия хондроитина сульфата и глюкозамина сульфата при саркопении. Неврология, нейропсихиатрия, психосоматика. 2019; 11 (1): 117–24. DOI: 10.14412/2074-2711-2019-1-117-124.
[Gromova O.A., Torshin I.Iu., Lila A.M. et al. Molekuliarnye mekhanizmy mioprotektivnogo deistviia khondroitina sul'fata i gliukozamina sul'fata pri sarkopenii. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2019; 11 (1): 117–24. DOI: 10.14412/2074-2711-2019-1-117-124 (in Russian).]
18. Громова О.А., Торшин И.Ю., Лила А.М. и др. Дифференциальный хемореактомный анализ глюкозамина сульфата и нестероидных противовоспалительных препаратов: перспективные синергичные комбинации. Соврем. ревматология. 2018; 12 (2): 36–43.
[Gromova O.A., Torshin I.Iu., Lila A.M. et al. Differentsial'nyi khemoreaktomnyi analiz gliukozamina sul'fata i nesteroidnykh protivovospalitel'nykh preparatov: perspektivnye sinergichnye kombinatsii. Sovrem. revmatologiia. 2018; 12 (2): 36–43 (in Russian).]
19. Торшин И.Ю., Громова О.А., Лила А.М. и др. Результаты постгеномного анализа молекулы глюкозамина сульфата указывают на перспективы лечения коморбидных заболеваний. Соврем. ревматология. 2018; 12 (4): 129–36.
[Torshin I.Iu., Gromova O.A., Lila A.M. et al. Rezul'taty postgenomnogo analiza molekuly gliukozamina sul'fata ukazyvaiut na perspektivy lecheniia komorbidnykh zabolevanii. Sovrem. revmatologiia. 2018; 12 (4): 129–36 (in Russian).]
20. Shi H, Munk A, Nielsen TS et al. Skeletal muscle O-GlcNAc transferase is important for muscle energy homeostasis and whole-body insulin sensitivity. Mol Metab 2018; 11: 160–77. DOI: 10.1016/j.molmet.2018.02.010. PMID: 29525407.
21. Lazarus MB, Jiang J, Gloster TM et al. Structural snapshots of the reaction coordinate for O-GlcNAc transferase. Nat Chem Biol 2012; 8 (12): 966–8. DOI: 10.1038/nchembio.1109. PMID: 23103939; PMCID: PMC3508357.
22. Lorenzo C, Festa A, Hanley AJ et al. Novel Protein Glycan-Derived Markers of Systemic Inflammation and C-Reactive Protein in Relation to Glycemia, Insulin Resistance, and Insulin Secretion. Diabetes Care 2017; 40 (3): 375–82. DOI: 10.2337/dc16-1569. PMID: 28031420.
23. Banerjee PS, Lagerlof O, Hart GW. Roles of O-GlcNAc in chronic diseases of aging. Mol Aspects Med 2016; 51: 1–15. DOI: 10.1016/j.mam.2016.05.005. PMID: 27259471.
24. Hwang SY, Shin JH, Hwang JS. Glucosamine exerts a neuroprotective effect via suppression of inflammationin rat brain ischemia/reperfusion injury. Glia 2010; 58 (15): 1881–92. DOI: 10.1002/glia.21058. PMID: 20737476.
25. Whelan SA, Dias WB, Thiruneelakantapillai L et al. Regulation of insulin receptor substrate 1 (IRS-1)/AKT kinase-mediated insulin signaling by O-Linked beta-N-acetylglucosamine in 3T3-L1 adipocytes. J Biol Chem 2010; 285 (8): 5204–11. DOI: 10.1074/jbc.M109.077818. PMID: 20018868
26. Baldini SF, Steenackers A, Olivier-Van Stichelen S. Glucokinase expression is regulated by glucose through O-GlcNAc glycosylation. Biochem Biophys Res Commun 2016; 478 (2): 942–8. DOI: 10.1016/j.bbrc.2016.08.056. PMID: 27520373.
27. Park S, Pak J, Jang I, Cho JW. Inhibition of mTOR affects protein stability of OGT. Biochem Biophys Res Commun 2014; 453 (2): 208–12. DOI: 10.1016/j.bbrc.2014.05.047. PMID: 24858682.
28. Al-Kurdi ZI, Chowdhry BZ, Leharne SA et al. Influence of glucosamine on the bioactivity of insulin delivered subcutaneously and in an oral nanodelivery system. Drug Des Devel Ther 2015; 9: 6167–76. DOI: 10.2147/DDDT.S91974. PMID: 26640369.
29. Chien MW, Lin MH, Huang SH et al. Glucosamine Modulates T Cell Differentiation through Down-regulating N-Linked Glycosylation of CD25. J Biol Chem 2015; 290 (49): 29329–44. DOI: 10.1074/jbc.M115.674671. PMID: 26468284.
30. Barrientos C, Racotta R, Quevedo L. Glucosamine attenuates increases of intraabdominal fat, serum leptin levels, and insulin resistance induced by a high-fat diet in rats. Nutr Res 2010; 30 (11): 791–800. DOI: 10.1016/j.nutres.2010.10.008. PMID: 21130299
31. Balkan B, Dunning BE. Glucosamine inhibits glucokinase in vitro and produces a glucose-specific impairment of in vivo insulin secretion in rats. Diabetes 1994; 43 (10): 1173–9. PMID: 7926284.
32. Simon RR, Marks V, Leeds AR, Anderson JW. A comprehensive review of oral glucosamine use and effects on glucose metabolism in normal and diabetic individuals. Diabetes Metab Res Rev 2011; 27 (1): 14–27. DOI: 10.1002/dmrr.1150. PMID: 21218504.
33. Tannis AJ, Barban J, Conquer JA. Effect of glucosamine supplementation on fasting and non-fasting plasma glucose and serum insulin concentrations in healthy individuals. Osteoarthritis Cartilage 2004; 12 (6): 506–11. DOI: 10.1016/j.joca.2004.03.001. PMID: 15135147.
34. Saghafi M, Karimi M, Bonakdaran S, Massoudnia N. Oral Glucosamine Effect on Blood Glucose and Insulin Levels in Patients With Non-Diabetic Osteoarthritis: A Double-Blind, Placebo-Controlled Clinical Trial. Arch Rheumatol 2016; 31 (4): 340–5. DOI: 10.5606/ArchRheumatol.2016.5632. PMID: 30375553.
35. Gommans YMM, Runhaar J, Jacobs ML, Bierma-Zeinstra SMA. The Effect of Prolonged Glucosamine Usage on HbA1c Levels and New-Onset Diabetes Mellitus in Overweight and Obese Middle-Aged Women. Am J Med 2017; 130 (6): 731–7.e6. DOI: 10.1016/j.amjmed.2016.11.038. PMID: 28011309.
36. Albert SG, Oiknine RF, Parseghian S et al. The effect of glucosamine on Serum HDL cholesterol and apolipoprotein AI levels in people with diabetes. Diabetes Care 2007; 30 (11): 2800–3. DOI: 10.2337/dc07-0545. PMID: 17682119.
37. Scroggie DA, Albright A, Harris MD. The effect of glucosamine-chondroitin supplementation on glycosylated hemoglobin levels in patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized clinical trial. Arch Intern Med 2003; 163 (13): 1587–90. DOI: 10.1001/archinte.163.13.1587. PMID: 12860582.
38. Nevado-Holgado AJ, Kim CH, Winchester L et al. Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK Biobank. BMJ Open 2016; 6 (11): e012177. DOI: 10.1136/bmjopen-2016-012177. PMID: 27903560.
39. Наумов А.В., Ткачева О.Н., Ховасова Н.О. Обострения хронической боли в спине у коморбидных больных: терапия на перспективу. РМЖ. Медицинское обозрение. 2018; 5: 35–42.
[Naumov A.V., Tkacheva O.N., Khovasova N.O. Obostreniia khronicheskoi boli v spine u komorbidnykh bol'nykh: terapiia na perspektivu. RMZh. Meditsinskoe obozrenie. 2018; 5: 35–42 (in Russian).]
40. Удовика М.И. Сравнительная эффективность инъекционных и пероральных симптоматических препаратов медленного действия в терапии первичного и посттравматического остеоартроза коленных суставов. РМЖ. 2017; 4: 446–50.
[Udovika M.I. Sravnitel'naia effektivnost' in"ektsionnykh i peroral'nykh simptomaticheskikh preparatov medlennogo deistviia v terapii pervichnogo i posttravmaticheskogo osteoartroza kolennykh sustavov. RMZh. 2017; 4: 446–50 (in Russian).]
41. Рандомизированное слепое многоцентровое плацебо-контролируемое клиническое исследование по изучению эффективности и безопасности препарата Сустагард® Артро, раствор для внутримышечного введения (ЗАО «ФармФирма “Сотекс”», Россия) у пациентов с остеоартрозом коленного сустава (гонартрозом) в параллельных группах, РКИ №60 от 12.02.2014, Фаза исследования III. Обращение к сайту 25 марта 2019. http://grls.rosminzdrav.ru
[Randomizirovannoe slepoe mnogotsentrovoe platsebo-kontroliruemoe klinicheskoe issledovanie po izucheniiu effektivnosti i bezopasnosti preparata SustagardR Artro, rastvor dlia vnutrimyshechnogo vvedeniia (ZAO "FarmFirma “Soteks”", Rossiia) u patsientov s osteoartrozom kolennogo sustava (gonartrozom) v parallel'nykh gruppakh, RKI №60 ot 12.02.2014, Faza issledovaniia III. Obrashchenie k saitu 25 marta 2019. http://grls.rosminzdrav.ru (in Russian).]
42. Четина Е.В., Шарапова Е.П., Кашеварова Н.Г. и др. Экспрессия генов метаболизма глюкозы и деструкции суставов при развитии сахарного диабета у больных остеоартритом. Соврем. ревматология. 2019; 13 (1): 64–70.
[Chetina E.V., Sharapova E.P., Kashevarova N.G. et al. Ekspressiia genov metabolizma gliukozy i destruktsii sustavov pri razvitii sakharnogo diabeta u bol'nykh osteoartritom. Sovrem. revmatologiia. 2019; 13 (1): 64–70 (in Russian).]
________________________________________________
2. Bianchi L, Volpato S. Muscle dysfunction in type 2 diabetes: a major threat to patient's mobility and independence. Acta Diabetol 2016; 53 (6): 879–89. DOI: 10.1007/s00592-016-0880-y. PMID: 27393005.
3. Reginato AM, Riera H, Vera M et al. Osteoarthritis in Latin America: Study of Demographic and Clinical Characteristics in 3040 Patients. J Clin Rheumatol 2015; 21 (8): 391–7. DOI: 10.1097/RHU.0000000000000281. PMID: 26457483.
4. Gromova O.A., Torshin I.Iu., Lila A.M., Gromov A.N. Molekuliarnye mekhanizmy gliukozamina sul'fata pri lechenii degenerativno-distroficheskikh zabolevanii sustavov i pozvonochnika: rezul'taty proteomnogo analiza. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2018; 10 (2): 38–44. DOI: 10.14412/2074-2711-2018-2-38-44 (in Russian).
5. Lila A.M., Gromova O.A., Torshin I.Iu. et al. Molekuliarnye effekty khondrogarda pri osteoartrite i gryzhakh mezhpozvonochnogo diska. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2017; 9 (3): 88–97 (in Russian).
6. Melgar-Lesmes P, Garcia-Polite F, Del-Rey-Puech P et al. Treatment with chondroitin sulfate to modulate inflammation and atherogenesis in obesity. Atherosclerosis 2015; 245: 82–7.
7. Bell GA, Kantor ED, Lampe JW et al. Use of Glucosamine and Chondroitin in Relation to Mortality. Eur J Epidemiol 2012; 27 (8): 593–603.
8. Lenox CE, Lunn KF. Effects of glucosamine-chondroitin sulfate supplementation on serum fructosamine concentration in healthy dogs. J Am Vet Med Assoc 2010; 236 (2): 183–6. DOI: 10.2460/javma.236.2.183. PMID: 20074008.
9. Stumpf JL, Lin SW. Effect of glucosamine on glucose control. Ann Pharmacother 2006; 40 (4): 694–8. DOI: 10.1345/aph.1E658. PMID: 16569816.
10. Torshin IYu, Rudakov KV. On the theoretical basis of metric analysis of poorly formalized problems of recognition and classification. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications) 2015; 25 (4): 577–87.
11. Torshin IY, Rudakov KV. On metric spaces arising during formalization of problems of recognition and classification. Part 1: properties of compactness. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications) 2016; 26 (2): 274–84.
12. Torshin IYu, Rudakov KV. On metric spaces arising during formalization of problems of recognition and classification. Рart 2: density properties. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications) 2016, 26 (3): 483–96.
13. Torshin IY, Rudakov KV. Combinatorial analysis of the solvability properties of the problems of recognition and completeness of algorithmic models. Рart 1: factorization approach. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications) 2017; 27 (1): 16–28.
14. Torshin IYu, Rudakov KV. Combinatorial analysis of the solvability properties of the problems of recognition and completeness of algorithmic models. Part 2: metric approach within the framework of the theory of classification of feature values. Pattern Recognition and Image Analysis (Advances in Mathematical Theory and Applications) 2017; 27 (2): 184–99.
15. Garcilazo C, Cavallasca JA, Musuruana JL. Shoulder manifestations of diabetes mellitus. Curr Diabetes Rev 2010; 6 (5): 334–40. PMID: 20701586.
16. Veronese N, Cooper C, Reginster JY et al. Type 2 diabetes mellitus and osteoarthritis. Semin Arthritis Rheum 2019; 18: 30586–9. DOI: 10.1016/j.semarthrit.2019.01.005. PMID: 30712918.
17. Gromova O.A., Torshin I.Iu., Lila A.M. et al. Molekuliarnye mekhanizmy mioprotektivnogo deistviia khondroitina sul'fata i gliukozamina sul'fata pri sarkopenii. Nevrologiia, neiropsikhiatriia, psikhosomatika. 2019; 11 (1): 117–24. DOI: 10.14412/2074-2711-2019-1-117-124 (in Russian).
18. Gromova O.A., Torshin I.Iu., Lila A.M. et al. Differentsial'nyi khemoreaktomnyi analiz gliukozamina sul'fata i nesteroidnykh protivovospalitel'nykh preparatov: perspektivnye sinergichnye kombinatsii. Sovrem. revmatologiia. 2018; 12 (2): 36–43 (in Russian).
19. Torshin I.Iu., Gromova O.A., Lila A.M. et al. Rezul'taty postgenomnogo analiza molekuly gliukozamina sul'fata ukazyvaiut na perspektivy lecheniia komorbidnykh zabolevanii. Sovrem. revmatologiia. 2018; 12 (4): 129–36 (in Russian).
20. Shi H, Munk A, Nielsen TS et al. Skeletal muscle O-GlcNAc transferase is important for muscle energy homeostasis and whole-body insulin sensitivity. Mol Metab 2018; 11: 160–77. DOI: 10.1016/j.molmet.2018.02.010. PMID: 29525407.
21. Lazarus MB, Jiang J, Gloster TM et al. Structural snapshots of the reaction coordinate for O-GlcNAc transferase. Nat Chem Biol 2012; 8 (12): 966–8. DOI: 10.1038/nchembio.1109. PMID: 23103939; PMCID: PMC3508357.
22. Lorenzo C, Festa A, Hanley AJ et al. Novel Protein Glycan-Derived Markers of Systemic Inflammation and C-Reactive Protein in Relation to Glycemia, Insulin Resistance, and Insulin Secretion. Diabetes Care 2017; 40 (3): 375–82. DOI: 10.2337/dc16-1569. PMID: 28031420.
23. Banerjee PS, Lagerlof O, Hart GW. Roles of O-GlcNAc in chronic diseases of aging. Mol Aspects Med 2016; 51: 1–15. DOI: 10.1016/j.mam.2016.05.005. PMID: 27259471.
24. Hwang SY, Shin JH, Hwang JS. Glucosamine exerts a neuroprotective effect via suppression of inflammationin rat brain ischemia/reperfusion injury. Glia 2010; 58 (15): 1881–92. DOI: 10.1002/glia.21058. PMID: 20737476.
25. Whelan SA, Dias WB, Thiruneelakantapillai L et al. Regulation of insulin receptor substrate 1 (IRS-1)/AKT kinase-mediated insulin signaling by O-Linked beta-N-acetylglucosamine in 3T3-L1 adipocytes. J Biol Chem 2010; 285 (8): 5204–11. DOI: 10.1074/jbc.M109.077818. PMID: 20018868
26. Baldini SF, Steenackers A, Olivier-Van Stichelen S. Glucokinase expression is regulated by glucose through O-GlcNAc glycosylation. Biochem Biophys Res Commun 2016; 478 (2): 942–8. DOI: 10.1016/j.bbrc.2016.08.056. PMID: 27520373.
27. Park S, Pak J, Jang I, Cho JW. Inhibition of mTOR affects protein stability of OGT. Biochem Biophys Res Commun 2014; 453 (2): 208–12. DOI: 10.1016/j.bbrc.2014.05.047. PMID: 24858682.
28. Al-Kurdi ZI, Chowdhry BZ, Leharne SA et al. Influence of glucosamine on the bioactivity of insulin delivered subcutaneously and in an oral nanodelivery system. Drug Des Devel Ther 2015; 9: 6167–76. DOI: 10.2147/DDDT.S91974. PMID: 26640369.
29. Chien MW, Lin MH, Huang SH et al. Glucosamine Modulates T Cell Differentiation through Down-regulating N-Linked Glycosylation of CD25. J Biol Chem 2015; 290 (49): 29329–44. DOI: 10.1074/jbc.M115.674671. PMID: 26468284.
30. Barrientos C, Racotta R, Quevedo L. Glucosamine attenuates increases of intraabdominal fat, serum leptin levels, and insulin resistance induced by a high-fat diet in rats. Nutr Res 2010; 30 (11): 791–800. DOI: 10.1016/j.nutres.2010.10.008. PMID: 21130299
31. Balkan B, Dunning BE. Glucosamine inhibits glucokinase in vitro and produces a glucose-specific impairment of in vivo insulin secretion in rats. Diabetes 1994; 43 (10): 1173–9. PMID: 7926284.
32. Simon RR, Marks V, Leeds AR, Anderson JW. A comprehensive review of oral glucosamine use and effects on glucose metabolism in normal and diabetic individuals. Diabetes Metab Res Rev 2011; 27 (1): 14–27. DOI: 10.1002/dmrr.1150. PMID: 21218504.
33. Tannis AJ, Barban J, Conquer JA. Effect of glucosamine supplementation on fasting and non-fasting plasma glucose and serum insulin concentrations in healthy individuals. Osteoarthritis Cartilage 2004; 12 (6): 506–11. DOI: 10.1016/j.joca.2004.03.001. PMID: 15135147.
34. Saghafi M, Karimi M, Bonakdaran S, Massoudnia N. Oral Glucosamine Effect on Blood Glucose and Insulin Levels in Patients With Non-Diabetic Osteoarthritis: A Double-Blind, Placebo-Controlled Clinical Trial. Arch Rheumatol 2016; 31 (4): 340–5. DOI: 10.5606/ArchRheumatol.2016.5632. PMID: 30375553.
35. Gommans YMM, Runhaar J, Jacobs ML, Bierma-Zeinstra SMA. The Effect of Prolonged Glucosamine Usage on HbA1c Levels and New-Onset Diabetes Mellitus in Overweight and Obese Middle-Aged Women. Am J Med 2017; 130 (6): 731–7.e6. DOI: 10.1016/j.amjmed.2016.11.038. PMID: 28011309.
36. Albert SG, Oiknine RF, Parseghian S et al. The effect of glucosamine on Serum HDL cholesterol and apolipoprotein AI levels in people with diabetes. Diabetes Care 2007; 30 (11): 2800–3. DOI: 10.2337/dc07-0545. PMID: 17682119.
37. Scroggie DA, Albright A, Harris MD. The effect of glucosamine-chondroitin supplementation on glycosylated hemoglobin levels in patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized clinical trial. Arch Intern Med 2003; 163 (13): 1587–90. DOI: 10.1001/archinte.163.13.1587. PMID: 12860582.
38. Nevado-Holgado AJ, Kim CH, Winchester L et al. Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK Biobank. BMJ Open 2016; 6 (11): e012177. DOI: 10.1136/bmjopen-2016-012177. PMID: 27903560.
39. Naumov A.V., Tkacheva O.N., Khovasova N.O. Obostreniia khronicheskoi boli v spine u komorbidnykh bol'nykh: terapiia na perspektivu. RMZh. Meditsinskoe obozrenie. 2018; 5: 35–42 (in Russian).
40. Udovika M.I. Sravnitel'naia effektivnost' in"ektsionnykh i peroral'nykh simptomaticheskikh preparatov medlennogo deistviia v terapii pervichnogo i posttravmaticheskogo osteoartroza kolennykh sustavov. RMZh. 2017; 4: 446–50 (in Russian).
41. Randomizirovannoe slepoe mnogotsentrovoe platsebo-kontroliruemoe klinicheskoe issledovanie po izucheniiu effektivnosti i bezopasnosti preparata SustagardR Artro, rastvor dlia vnutrimyshechnogo vvedeniia (ZAO "FarmFirma “Soteks”", Rossiia) u patsientov s osteoartrozom kolennogo sustava (gonartrozom) v parallel'nykh gruppakh, RKI №60 ot 12.02.2014, Faza issledovaniia III. Obrashchenie k saitu 25 marta 2019. http://grls.rosminzdrav.ru (in Russian).
42. Chetina E.V., Sharapova E.P., Kashevarova N.G. et al. Ekspressiia genov metabolizma gliukozy i destruktsii sustavov pri razvitii sakharnogo diabeta u bol'nykh osteoartritom. Sovrem. revmatologiia. 2019; 13 (1): 64–70 (in Russian).
Авторы
О.А.Громова*1,2, И.Ю.Торшин1,2, А.М.Лила3, А.В.Наумов4, К.В.Рудаков1,2
1 Федеральный исследовательский центр «Информатика и управление» Российской академии наук, Москва, Россия;
1 Федеральный исследовательский центр «Информатика и управление» Российской академии наук, Москва, Россия;
2 Центр хранения и анализа больших данных ФГБОУ ВО «Московский государственный университет им. М.В.Ломоносова», Москва, Россия;
3 ФГБНУ «Научно-исследовательский институт ревматологии им. В.А.Насоновой», Москва, Россия;
4 ФГБОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И.Пирогова» Минздрава России, Москва, Россия
________________________________________________
Olga A. Gromova*1,2, Ivan Iu. Torshin1,2, Aleksandr M. Lila3, Anton V. Naumov4, Konstantin V. Rudakov1,2
1 Federal Research Center «Computer Science and Control» of the Russian Academy of Sciences, Moscow, Russia;
1 Federal Research Center «Computer Science and Control» of the Russian Academy of Sciences, Moscow, Russia;
2 Center for Big Data Storage and Analysis Technologies, M.V.Lomonosov Moscow State University, Moscow, Russia;
3 V.A.Nasonova Research Institute of Rheumatology, Moscow, Russia;
4 Pirogov Russian National Research Medical University, Moscow, Russia
*unesco.gromova@gmail.com
3 V.A.Nasonova Research Institute of Rheumatology, Moscow, Russia;
4 Pirogov Russian National Research Medical University, Moscow, Russia
*unesco.gromova@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.